EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML

Nicholas J Short iD, Naval Daver iD, Courtney D Dinardo iD, Tapan Kadia iD, Lewis F Nasr iD, Walid Macaron, Musa Yilmaz, Gautam Borthakur iD, Guillermo Montalban-Bravo, Guillermo Garcia-Manero iD, Ghayas C Issa iD, Kelly S Chien iD und 12 weitere

Journal of Clinical Oncology · 01.05.2024 · 42 (13) · 1499-1508

DOI: 10.1200/jco.23.01911 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.05.2024. Verfasst von Nicholas J Short und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols, Sulfonamides. Die Arbeit wurde bisher 203-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Azacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, FLT3 mutations are a common mechanism of resistance to this regimen. The addition of gilteritinib, an oral FLT3 inhibitor, to azacitidine and venetoclax may improve outcomes in patients with FLT3-mutated AML. METHODS This phase I/II study evaluated azacitidine, venetoclax, and gilteritinib in two cohorts: patients with (1) newly diagnosed FLT3-mutated AML who were unfit for intensive chemotherapy or (2) relapsed/refractory FLT3-mutated AML (ClinicalTrials.gov identifier: NCT04140487 ). The primary end points were the maximum tolerated dose of gilteritinib (phase I) and the combined complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate (phase II). RESULTS Fifty-two patients were enrolled (frontline [n = 30]; relapsed/refractory [n = 22]). The recommended phase II dose was gilteritinib 80 mg once daily in combination with azacitidine and venetoclax. In the frontline cohort, the median age was 71 years and 73% of patients had an FLT3-internal tandem duplication (ITD) mutation. The CR/CRi rate was 96% (CR, 90%; CRi, 6%). Sixty-five percent of evaluable patients achieved FLT3-ITD measurable residual disease

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy ProtocolsSulfonamidesAniline CompoundsMutationBridged Bicyclo Compounds, HeterocyclicPyrazinesAzacitidineHumansMiddle AgedMaleAgedFemaleAdultAged, 80 and overDrug Resistance, Neoplasm

Substanzen

gilteritinibvenetoclaxfms-Like Tyrosine Kinase 3SulfonamidesAniline CompoundsBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanPyrazinesAzacitidine

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Nicholas J Short, Naval Daver, Courtney D Dinardo, Tapan Kadia, Lewis F Nasr, Gautam Borthakur, Guillermo Garcia-Manero, Ghayas C Issa, Kelly S Chien, Elias Jabbour, Cedric Nasnas, Xuelin Huang, Wei Qiao, Keyur P Patel, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi

Förderung

  • NCI NIH HHS

Zitieren

APA

Short, N. J., Daver, N., Dinardo, C. D., Kadia, T., Nasr, L. F., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G. C., Chien, K. S., Jabbour, E., Nasnas, C., Huang, X., Qiao, W., Matthews, J., Stojanik, C. J., Patel, K. P., …, & Ravandi, F. (2024). Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML. Journal of Clinical Oncology, 42(13), 1499-1508. https://doi.org/10.1200/jco.23.01911

Vancouver

Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML. Journal of Clinical Oncology. 2024;42(13):1499-1508. doi:10.1200/jco.23.01911

BibTeX
@article{Short2024,
  author = {Short, Nicholas J and Daver, Naval and Dinardo, Courtney D and Kadia, Tapan and Nasr, Lewis F and Macaron, Walid and Yilmaz, Musa and Borthakur, Gautam and Montalban-Bravo, Guillermo and Garcia-Manero, Guillermo and Issa, Ghayas C and Chien, Kelly S and Jabbour, Elias and Nasnas, Cedric and Huang, Xuelin and Qiao, Wei and Matthews, Jairo and Stojanik, Christopher J and Patel, Keyur P and Abramova, Regina and Thankachan, Jennifer and Konopleva, Marina and Kantarjian, Hagop and Ravandi, Farhad},
  title = {Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {13},
  pages = {1499--1508},
  doi = {10.1200/jco.23.01911}
}
Kostenlos starten →